Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Last trade$2.15
Day change+$0.07 (+3.37%)
Day range$2.02 – $2.19
Volume244,444
Market cap$35M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$35.46M
Price / earnings
—
Price / book
1.25×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.42×
Profitability
Earnings per share
-$0.80
Return on assets
-36.75%
Return on equity
-47.96%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.42×
Quick ratio
4.42×
Cash ratio
3.88×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$26.04M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VERU, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.36M
$4.07M
$4.08M
$4.54M
$5.01M
$5.16M
$5.23M
$6.25M
Research and development
$4.35M
$3.15M
$1.34M
$2.92M
$3.02M
$3.93M
$5.72M
$3.29M
Total operating expenses
$7.71M
$7.22M
$5.42M
$7.46M
$8.03M
$9.1M
$10.94M
$9.54M
Operating income
-$7.71M
-$7.22M
-$5.42M
-$7.46M
-$8.03M
-$9.1M
-$10.94M
-$9.54M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$6.99M
-$3.09M
-$5.33M
$1.3M
-$7.32M
-$7.85M
-$1.81M
-$8.55M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.99M
-$2.74M
-$5.33M
$1.45M
-$7.33M
-$7.9M
-$8.95M
-$8.53M
Net income attributable to common shareholders
-$6.99M
-$2.74M
-$5.33M
$1.45M
-$7.33M
-$7.9M
-$8.95M
-$8.53M
EBITDA
-$7.69M
-$7.19M
-$5.4M
-$7.43M
-$8M
-$9.07M
-$10.88M
-$9.47M
Basic earnings per share
-$0.30
-$0.12
-$0.26
$0.10
-$0.50
-$0.54
-$0.61
-$0.58
Diluted earnings per share
-$0.30
-$0.12
-$0.26
$0.10
-$0.50
-$0.54
-$0.61
-$0.58
Recent news
Company coverage with links to the original publishers.
Veru sells its FC2 Female Condom business for $18 million, reducing its workforce by 90% and refocusing on its biopharma pipeline, including late-stage trials for enobosarm to treat weight loss in GLP-1-treated patients.
Veru Inc. has sold its FC2 Female Condom business for $18 million, allowing the company to focus on its late-stage biopharmaceutical pipeline, including a Phase 2b clinical trial evaluating enobosarm to preserve muscle and augment fat loss in patients receiving the GLP-1 receptor agonist Wegovy.
The sexual wellness market is expected to grow at a CAGR of 4.7% by 2031, driven by increasing awareness of sexual health and the availability of a wide range of products. However, social stigma and regulatory challenges remain as key restraints.
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in the Leerink Therapeutics Forum: I&I and Metabolism on July 9th, 2024, in Boston, Massachusetts.
MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from two late-breaker presentations at the American Diabetes Association's 84th Scientific Sessions, which took place on June 21-24, 2024, in Orlando, Florida.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Apr 28, 2014
$0.70
May 7, 2014
recurring
Jan 27, 2014
$0.70
Feb 5, 2014
recurring
Oct 28, 2013
$0.70
Nov 6, 2013
recurring
Jul 29, 2013
$0.70
Aug 7, 2013
recurring
Apr 29, 2013
$0.70
May 8, 2013
recurring
Stock splits
Historical share-structure events and their execution dates.